Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 9,654 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Completed Phase 1 Interventional

A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors

NCT00858377
View directory record Official record
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Solid Tumors, Tumors
Interventions
Arm 1- Dose Escalation, Arm 1- Dose Expansion
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Phase 1 Interventional

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

NCT04006301
View directory record Official record
Conditions
Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
JNJ-74699157
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sarasota, Florida • Tampa, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 28, 2026, 10:51 PM EDT
Terminated Phase 1 Interventional

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

NCT01019681
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Cord blood stem cell injection
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
18 Years to 72 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 28, 2026, 10:51 PM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

NCT07504588
View directory record Official record
Conditions
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 10:51 PM EDT
Terminated Phase 1Phase 2 Interventional

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

NCT00945269
View directory record Official record
Conditions
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, polymerase chain reaction
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 28, 2026, 10:51 PM EDT
Recruiting Phase 1 Interventional

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT06622005
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib, Dexamethasone, Biospecimen Collection, Bone Marrow Aspiration, Echocardiography, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 10:51 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

GETSmart: Guided Education and Training Via Smart Phones to Promote Resilience

NCT02170194
View directory record Official record
Conditions
Subthreshold PTSD
Interventions
Resilience Enhancement Training via Smart Phone, Daily Text Messages
Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

NCT00393029
View directory record Official record
Conditions
Anti-p53 TCR-Gene
Interventions
anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Radiation Dose in Humans From Orally Administered Tc99m-Heparin

NCT04069429
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Computerized Tomography scan, Single Photon Emission Computed Tomography scans, Technetium Tc 99M, Planar Images, Esophagogastroduodenoscopy
Radiation · Drug · Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

NCT00425503
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
PS-341 (bortezomib)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance

NCT01871142
View directory record Official record
Conditions
Hypoxia
Interventions
Placebo, Aes-103
Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Phase 1 Interventional

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

NCT03562494
View directory record Official record
Conditions
Parkinson's Disease
Interventions
VY-AADC02, Sham (Placebo) Surgery
Biological · Other
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Irvine, California • Sacramento, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 28, 2026, 10:51 PM EDT
Active, not recruiting Phase 2 Interventional

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT03844061
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Not applicable Interventional

Goals for Reaching Optimum Wellness (GROWell)

NCT02904473
View directory record Official record
Conditions
Pregnant Women
Interventions
GROWell
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing Uniqueness of Inflammatory Bowel Disease Related Microbiome-derived Biomarkers

NCT05640583
View directory record Official record
Conditions
Irritable Bowel Disease
Interventions
Hygieacare System
Device
Lead sponsor
HyGIeaCare, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 28, 2026, 10:51 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

NCT05694741
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD0186, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Perceptual Experience of Argus II Users

NCT05285618
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Argus II
Device
Lead sponsor
University of California, Santa Barbara
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Santa Barbara, California • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 28, 2026, 10:51 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Trimodulin, Placebo (human albumin 1%)
Drug
Lead sponsor
Biotest
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Early Phase 1 Interventional Results available

Dronabinol Interactions With Cognitive Enhancing Drug in Humans

NCT00842985
View directory record Official record
Conditions
Cannabis, Marijuana Abuse
Interventions
drug condition
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women

NCT04475718
View directory record Official record
Conditions
Pregnancy Related, Postpartum Sadness
Interventions
Fourth Trimester Mobile Tool
Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Watertown, Massachusetts • Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 28, 2026, 10:51 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

NCT04064060
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Interventions
Luspatercept
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
12
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 28, 2026, 10:51 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections

NCT04763759
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
TRL1068, a human monoclonal antibody
Drug
Lead sponsor
Trellis Bioscience LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 28, 2026, 10:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

NCT03416335
View directory record Official record
Conditions
Neoplasms
Interventions
DSP-0509, DSP-0509, Pembrolizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Indianapolis, Indiana • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 28, 2026, 10:51 PM EDT